Journal articles
Clinical Development of Mepolizumab for the Treatment of Severe Eosinophilic Asthma: On the Path to Personalized Medicine
Ian Pavord
Andrew Menzies-Gow
Roland Buhl
Pascal Chanez
1
Mark Dransfield
Njira Lugogo
Oliver Keene
Eric Bradford
Steve Yancey
Steve Yancey
Author
1
C2VN - Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (Faculté de Médecine de la Timone 27 boulevard Jean Moulin 13385 MARSEILLE CEDEX 5 - France)
- AMU - Aix Marseille Université : UMR_S1263 (Aix-Marseille Université Jardins du Pharo 58 Boulevard Charles Livon 13284 Marseille cedex 7 - France)
- INSERM - Institut National de la Santé et de la Recherche Médicale : UMR_S1263 (101, rue de Tolbiac, 75013 Paris - France)
- INRAE - Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement : UMR1260 (France)
Document type :
Journal articles
Domain :
Complete list of metadata
https://hal-amu.archives-ouvertes.fr/hal-03654311
Contributor : Guillaume Ranchon Connect in order to contact the contributor
Submitted on : Thursday, April 28, 2022 - 3:05:21 PM
Last modification on : Friday, April 29, 2022 - 3:38:24 AM
Contributor : Guillaume Ranchon Connect in order to contact the contributor
Submitted on : Thursday, April 28, 2022 - 3:05:21 PM
Last modification on : Friday, April 29, 2022 - 3:38:24 AM
Links full text
Identifiers
- HAL Id : hal-03654311, version 1
- DOI : 10.1016/j.jaip.2020.08.039
Citation
Ian Pavord, Andrew Menzies-Gow, Roland Buhl, Pascal Chanez, Mark Dransfield, et al.. Clinical Development of Mepolizumab for the Treatment of Severe Eosinophilic Asthma: On the Path to Personalized Medicine. The Journal of Allergy and Clinical Immunology: In Practice, American Academy of Allergy, Asthma & Immunology, 2021, 9 (3), pp.1121-1132.e7. ⟨10.1016/j.jaip.2020.08.039⟩. ⟨hal-03654311⟩
Metrics
Record views